Ex vivo T cell depletion (TCD), is? highly effective for lethal graft-vs.-host disease (GVHD) prevention.? However, T cell removal may compromise beneficial donor T cell responses.? Pharmacological agents are incompletely efficacious in preventing GVHD and? have significant side-effects. Rather than broadly eliminate T cells or T? cell subsets, the applicants propose to functionally alter ex vivo the small? proportion of donor T cells with anti-host alloreactive potential.
In aim ? 1, two types of ex vivo approaches are proposed to inhibit CD4+ T cell? mediated GVHD lethality. The first involves physically blocking the? interaction of cell surface determinants on donor T cells with those on host? antigen-presenting cells. The CD40L, CD40 and CD28/B7 pathways will be? targeted. The second involves targeting intracellular signalling pathways? (PI3K, Jak3) required for optimal T cell responses. A series of studies? using wild-type and various knockout (ko) mice are proposed in aim 1 which? will investigate the mechanism(s) responsible for inducing alloantigen? hyporesponsiveness.
In aim 2 A, successful tolerization approaches will be? applied to CD4+ and CD8+ T cell containing donor inoculum.
In aim 2 B, T? cell receptor (TCR) transgenic systems will be used to track CD4+ or CD8+? TCR clonotypes that are capable of specifically responding to alloantigen or? nominal antigen. These studies will provide important information regarding? the mechanism(s) responsible for tolerance induction and the specificity of? these approaches as measured by bystander effects on nominal antigen? responses.
In aim 2 C, the effects of tolerance induction on? graft-versus-leukemia (GVL) will be analyzed using a delayed lymphocyte? infusion model system. This application will provide new strategies for ex? vivo GVHD prevention and will provide important data on the mechanism(s) and? specificity of such approaches in clinically relevant model systems.?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37HL056067-13
Application #
7249416
Study Section
Special Emphasis Panel (NSS)
Program Officer
Barbosa, Luiz H
Project Start
1995-08-01
Project End
2008-07-31
Budget Start
2007-08-01
Budget End
2008-07-31
Support Year
13
Fiscal Year
2007
Total Cost
$435,801
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Pediatrics
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Sarhan, Dhifaf; Hippen, Keli L; Lemire, Amanda et al. (2018) Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunol Res 6:766-775
Zitzer, Nina C; Snyder, Katiri; Meng, Xiamoei et al. (2018) MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function. J Immunol 200:4170-4179
Tkachev, Victor; Furlan, Scott N; Watkins, Benjamin et al. (2017) Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant. Sci Transl Med 9:
Ranganathan, Parvathi; Ngankeu, Apollinaire; Zitzer, Nina C et al. (2017) Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding. J Immunol 198:2500-2512
Saha, Asim; O'Connor, Roddy S; Thangavelu, Govindarajan et al. (2016) Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest 126:2642-60
Veenstra, Rachelle G; Flynn, Ryan; Kreymborg, Katharina et al. (2015) B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood 125:3335-46
Singh, K; Stempora, L; Harvey, R D et al. (2014) Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. Am J Transplant 14:2691-703
Dubovsky, Jason A; Flynn, Ryan; Du, Jing et al. (2014) Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest 124:4867-76
Saha, Asim; Aoyama, Kazutoshi; Taylor, Patricia A et al. (2013) Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood 122:3062-73
Sharma, Madhav D; Huang, Lei; Choi, Jeong-Hyeon et al. (2013) An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity 38:998-1012

Showing the most recent 10 out of 85 publications